Actogenix
Also known as: Actogenix
Actogenix is a proprietary peptide-bioregulator-style product marketed for vitality, energy, and healthy-aging support. It is sold as a research chemical with limited published data.
Last updated
Mechanism of Action
Actogenix is positioned within the Khavinson-style short peptide bioregulator tradition, in which ultrashort peptides are proposed to bind regulatory regions of DNA and modulate tissue-specific gene expression. The marketed rationale centers on supporting cellular energy metabolism, mitochondrial function, and adaptive (actoprotector-like) resistance to physical and oxidative stress. Because its specific sequence and targets are not published in peer-reviewed sources, the mechanism remains inferred from the bioregulator and actoprotector classes rather than direct evidence.
- Half-life
- Not established; short bioregulator peptides are generally cleared within hours
- Administration Routes
- subcutaneous, oral
- Research Status
- Research Chemical
Reported Benefits
- Marketed for energy and physical-performance support
- Proposed adaptogenic and actoprotector-like effects
- Positioned for cellular and mitochondrial health
- Framed as supporting recovery from fatigue
- Marketed within a healthy-aging context
Potential Side Effects
- Poorly characterized safety profile
- Possible mild stimulation or sleep disturbance
- Injection-site reactions if administered subcutaneously
- Unknown long-term effects
Common Dosing
For research use only and not medical advice: short peptide bioregulators are typically referenced at low microgram-to-low-milligram amounts in short cyclical courses, oral or subcutaneous. No validated dosing exists for Actogenix specifically.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Pregnancy or breastfeeding
- Known peptide hypersensitivity
- Use without appropriate research oversight
CardioCytogen
CardioCytogen is a proprietary short-peptide bioregulator marketed for cardiovascular and heart-tissue support. It is sold as a research chemical with limited published characterization.
Epitalon
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) based on the pineal peptide epithalamin, studied for telomerase activation, circadian regulation, and longevity in animal and limited human research.
MOTS-c
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA region that acts as a regulator of metabolism. It is studied for improving insulin sensitivity, metabolic flexibility, and exercise capacity.
No notable studies catalogued for Actogenix yet.